CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Explore Ways to Fix Major Budgeting Mistakes by recalibrating spending, updating goals, and setting up durable budget processes.
17,830 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Venice AI has secured $65 million in a Series A round led by Dragonfly, valuing the company at $1 billion as it expan...
An executive stock sale can signal many things. This article breaks down the numbers, the reporting rules, and practi...
ADA pulled back after a sharp weekly surge, with derivatives data signaling waning momentum and potential shifts in t...
Broadcom climbs about 5% to around $390 after Apple expands its multiyear chip deal. Intel and AMD drift lower as inv...
A ChatGPT-powered forecast associated with Sam Altman lays out a bullish Bitcoin scenario for late 2026, highlighting...
Oil prices jumped as much as 5% after Iran claimed the Strait of Hormuz was closed, triggering a sharp rally in crude...
Morgan Stanley won preliminary approval to build an internal digital-asset bank. The plan would bring custody, stakin...
Bitcoin trades around the $63,000 mark as it confronts stubborn resistance and tests key support levels. Analysts war...
Public exoneration changes the financial landscape for families and business owners. This article explains how to tra...
Copper futures tumbled intraday as supply climbs and demand questions linger. The move pins attention on five NYSE-li...